ORLANDO -- Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in ...

Positive full results from the NATRON Phase III trial showed AstraZeneca’s Fasenra (benralizumab) demonstrated a ...

The novel, oral interleukin-23 inhibitor icotrokinra bested placebo in multiple skin outcomes among adolescent patients with ...

Researchers at the University of Illinois Urbana-Champaign report that extracellular vesicles released into the bloodstream ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.

Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third ...

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...

At AAO 2025, David Eichenbaum, Director of Research and partner at Retina Vitreous Associates of Florida, and collaborative ...